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OBJECTIVES We sought to determine prospectively whether lipoprotein-associated phospholipase A2
(Lp-PLA2) was a predictor of future cardiovascular risk in women.
BACKGROUND Inflammatory markers may help predict cardiovascular risk. Lp-PLA2 levels have recently
been hypothesized to be an independent predictor of cardiovascular risk in hypercholester-
olemic men.
METHODS We conducted a prospective, nested case-control study among 28,263 apparently healthy
middle-aged women to assess the risk of death from coronary heart disease, non-fatal
myocardial infarction, and stroke associated with baseline levels of Lp-PLA2 over a mean
follow-up of three years.
RESULTS In univariate analysis, mean levels of Lp-PLA2 correlated strongly with low-density
lipoprotein cholesterol (r  0.51; p  0.0001), were lower among women currently using
hormone replacement therapy (mean 0.98 mg/l vs. 1.23 mg/l; p  0.0001) and were
significantly higher at baseline among cases (n  123) than controls (n  123) (mean
1.20 mg/l vs. 1.05 mg/l; p 0.016). However, the predictive value of Lp-PLA2 was markedly
attenuated after adjustment for these and other cardiovascular risk factors. Specifically, the
multivariate relative risks of future cardiovascular events for women in the lowest (referent) to
highest quartiles of Lp-PLA2 were 1.00, 0.75, 0.64 and 1.17, respectively (all p values
non-significant). In contrast, the adjusted relative risks of future cardiovascular events for each
increasing quartile of C-reactive protein (another marker of low-grade inflammation) were
1.00, 1.78, 2.02 and 4.66, respectively (p-value for trend  0.002). Inclusion of Lp-PLA2
levels did not significantly attenuate this latter observation.
CONCLUSIONS In contrast to prior data among hyperlipidemic men, the current data suggest that Lp-PLA2
is not a strong predictor of future cardiovascular risk among unselected women. (J Am Coll
Cardiol 2001;38:1302–6) © 2001 by the American College of Cardiology
Inflammatory processes play a fundamental role in the
pathogenesis of atherosclerosis (1), and several inflamma-
tory biomarkers including high-sensitivity C-reactive pro-
tein (CRP), interleukin-6 and soluble intercellular adhesion
molecule-1 have been shown to predict future vascular risk
(2–11). Recently, lipoprotein-associated phospholipase A2
(Lp-PLA2) has been proposed as an inflammatory marker
of cardiovascular risk (12–14). This enzyme circulates in the
blood in association with low-density lipoprotein (LDL)
cholesterol. The synthesis of this enzyme is regulated by
inflammatory cytokines (15). Lp-PLA2 may contribute
directly to atherogenesis, by hydrolyzing oxidized phospho-
lipids into pro-atherogenic fragments and by generating
lysolecithin, which has pro-inflammatory properties (16).
Alternatively, Lp-PLA2 may have antithrombotic effects by
hydrolyzing platelet-activating factor (14,17).
Recently, Packard and colleagues reported in a cohort of
hypercholesterolemic men that increasing plasma levels of
Lp-PLA2 were a strong predictor of risk for incident
coronary heart disease (CHD) (13). We sought to test this
hypothesis prospectively in a lower-risk population of
women.
METHODS
The Women’s Health Study (WHS) is an ongoing random-
ized, double-blind, placebo-controlled trial of aspirin and
vitamin E being conducted among women age 45 years and
above with no history of cardiovascular disease or cancer
(18). Blood samples were collected in EDTA-containing
tubes from 28,263 (71%) of these women at baseline and
stored in liquid nitrogen until analysis.
Questionnaires are sent to WHS participants to elicit
information on cardiovascular risk factors and incident
cardiovascular events. For this analysis, cases were defined as
study participants who provided a baseline blood sample and
who subsequently had a cardiovascular event as defined by
death due to CHD, non-fatal myocardial infarction (MI) or
stroke. The mean follow-up period was three years.
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For all cases of MI, stroke or death due to CHD, hospital
records were obtained and reviewed. Myocardial infarction
was confirmed if symptoms met World Health Organiza-
tion criteria and if the event was associated with diagnostic
electrocardiographic changes or elevated cardiac enzymes.
Reported stroke was confirmed if the patient had a new
neurologic event persisting for more than 24 h; computed
tomography scans or magnetic resonance images were
available for the majority of women who developed stroke.
Death due to CHD was confirmed by review of autopsy
reports, death certificates, medical records and circum-
stances of death.
For each case who provided a baseline blood sample, one
control subject matched for age (within one year) and
smoking status (current, former or never) was selected from
among the remaining study participants who remained free
of cardiovascular events and who had also provided a blood
sample at baseline. Using these criteria, 123 cases and 123
controls were selected. The cases were composed of 63
women who had a non-fatal MI, 49 women who had a
stroke and 11 women who died from CHD.
Baseline plasma samples were thawed and assayed for
Lp-PLA2 with an enzyme-linked immunoassay as previ-
ously described (13). Samples were captured with a mono-
clonal antibody against Lp-PLA2 and the enzyme identified
with a second monoclonal antibody labeled with biotin and
a streptavidin-alkaline phosphatase conjugate. The standard
was purified recombinant Lp-PLA2 and there was no
cross-reactivity with other phospholipase A2 enzymes.
C-reactive protein assays were performed using a latex-
enhanced immunonephelometric assay on a BN II analyzer
(Dade Behring, Newark, Delaware) (19). Samples were
handled in a blinded fashion throughout the study.
The Student t test was used to evaluate differences in
means. Because the distribution of CRP was skewed,
differences in medians were tested with the rank-sum test.
The chi-square statistic was used to compare proportions.
Analysis of trends was used to test for any evidence of
association between increasing levels of each plasma marker
and the risk of future cardiovascular events, after the sample
was divided into quartiles according to the distribution of
each marker. Pearson’s coefficient was used to assess the
correlation between Lp-PLA2 and LDL cholesterol, high-
density lipoprotein (HDL) cholesterol and body mass index.
Logistic regression models were used to calculate relative
risks and 95% confidence intervals (CIs). In addition to
accounting for the variables used for matching (age and
smoking status), these models adjusted for random assign-
ment to aspirin or vitamin E. Further analyses were per-
formed that included LDL and HDL cholesterol, body
mass index, a history of hypertension, a history of diabetes,
a parental history of MI, frequency of exercise and current
use of hormone replacement therapy. All p values were
two-tailed.
RESULTS
The baseline clinical characteristics of the study population
are shown in Table 1. As expected, the women who had
cardiovascular events had a higher mean body mass index,
and were more likely to have a history of hypertension, a
Abbreviations and Acronyms
CI  confidence interval
CHD  coronary heart disease
CRP  C-reactive protein
HDL  high-density lipoprotein
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Lp-PLA2  lipoprotein-associated phospholipase A2
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WHS  Women’s Health Study
Table 1. Baseline Clinical Characteristics of the Study Population
Characteristic
Women With
Cardiovascular
Events
(Cases)
n  123
Women Free of
Cardiovascular
Events
(Controls)
n  123 p Value*
Mean age (yrs) (SD) 60.2 (8.3) 60.2 (8.3) —
Mean body mass index (kg/m2) (SD) 27.7 (5.5) 25.6 (4.8) 0.002
History of hypertension (%) 58.5 32.8 0.001
History of diabetes (%) 11.4 3.3 0.014
Parental history of myocardial infarction
before 60 years (%)
22.8 11.2 0.02
Smoking status (%) —
Current 28.5 28.5
Former 32.5 32.5
Never 39.0 39.0
Current use of hormone replacement
therapy (%)
43.9 41.5 0.7
Lp-PLA2 (mg/l) mean (SD) 1.20 (0.56) 1.05 (0.41) 0.016
CRP (mg/dl) median (interquartile range) 0.51 (0.26–0.85) 0.26 (0.12–0.49) 0.0001
* p values were not calculated for variables used in matching of case and control subjects, because the distribution of these
variables was identical between the two groups.
Lp-PLA2  lipoprotein-associated phospholipase A2; SD  standard deviation.
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history of diabetes, or a parental history of early MI (before
the age of 60 years) than women free from cardiovascular
events. Because of matching, cases and controls were almost
identical with respect to age and smoking status.
In univariate analyses, baseline levels of Lp-PLA2 were
higher among cases than controls (mean 1.20 mg/l vs. 1.05
mg/l; p  0.016) (Table 1). However, levels of Lp-PLA2
were also highly correlated with LDL cholesterol (r  0.51,
p  0.0001), as well as body mass index (r  0.22, p 
0.0007) and HDL cholesterol (r  0.34, p  0.0001).
Thus as shown in Table 2, after adjustment for these and
other cardiovascular risk factors, there was little evidence of
association between Lp-PLA2 and future cardiovascular
risk. Specifically, the adjusted relative risks from lowest
(referent) to highest quartiles of Lp-PLA2 at baseline were
1.00, 0.75, 0.64 and 1.17 (p-value for trend  0.8). In
comparison, the relative risks associated with each increas-
ing quartile of CRP, after adjustment for both lipid levels
and other traditional risk factors, were 1.00, 1.78, 2.02 and
4.66 respectively (p-value for trend  0.002) (Fig. 1). As
shown in Table 3, the adjusted risk of future cardiovascular
events increased by 62% for each quartile increase in CRP
(p  0.002), whereas the risk increased by 5% for each
quartile of Lp-PLA2, an effect that was not statistically
significant (p  0.8). These results were essentially un-
changed when both Lp-PLA2 and CRP were included in
the same model.
To determine whether there was a threshold effect above
which Lp-PLA2 levels conferred an increased risk, we
performed a post-hoc analysis in which we calculated the
relative risk of future cardiovascular events at different
cutoffs for Lp-PLA2 ranging from the 50th to the 95th
percentile. In this post-hoc analysis, women with levels
above the 95th percentile had a significantly increased
risk in univariate analyses (relative risk 2.67, 95% CI 1.06
to 6.69; p  0.04). Again, however, even among this small
subgroup of women with the very highest base-
line levels of Lp-PLA2, this effect was attenuated in
multivariate analysis (relative risk  2.08, 95% CI 0.69 to
6.30; p  0.2).
In subgroup analyses restricted to stroke as a separate
endpoint, for each quartile increase of Lp-PLA2 the crude
relative risk of stroke increased by 6% (95% CI 21% to
41%; p  0.7), whereas for each quartile increase of CRP
the crude relative risk of stroke increased by 78% (95% CI
28% to 248%; p  0.0006).
Lp-PLA2 levels were higher among women currently
not taking hormone replacement therapy (n  141) than
among women taking hormone replacement therapy
(n  105) (1.23 mg/l  vs. 0.98 mg/l  0.47; p  0.0001).
This finding is consistent with data from animal models
suggesting that estrogen decreases plasma Lp-PLA2
activity (20,21). Thus we examined for evidence of
effect modification according to current use of hormone
replacement therapy. In analyses restricted to women not
currently taking hormone replacement therapy, the unad-
justed relative risk of future cardiovascular events increased
by 29% with each quartile increase of Lp-PLA2 (95% CI
4% to 72%; p  0.09). This effect was attenuated in
adjusted analyses, where the relative risk increased by 7% for
each quartile increase of Lp-PLA2 (95% CI 29% to
62%; p  0.7). Among women currently taking hormone
replacement therapy, the relative risk of future cardiovascu-
lar events for each quartile increase of Lp-PLA2 increased
by 10% (95% CI21% to52%; p 0.6) in crude analysis
and 3% (95% CI 37% to 66%; p  0.9) in adjusted
analysis.
DISCUSSION
In this prospective study of healthy middle-aged women,
plasma levels of Lp-PLA2 were higher among women who
Table 2. Crude and Adjusted Relative Risks of Cardiovascular Events According to Quartile of Plasma Level of Lp-PLA2
Quartile of Plasma Level of Lp-PLA2 p Value
for Trend1 (lowest) 2 3 4 (highest)
Plasma level (mg/l) 0.77 0.78–1.01 1.02–1.29 1.30
Crude Analysis*
Relative risk 1 0.90 0.69 1.73 0.14
(95% CI) (0.43–1.85) (0.32–1.47) (0.87–3.44)
p value 0.76 0.33 0.12
Adjusted for LDL and HDL†
Relative risk 1 0.72 0.50 1.08 0.8
(95% CI) (0.34–1.51) (0.22–1.13) (0.48–2.43)
p value 0.38 0.10 0.86
Adjusted for LDL, HDL and
other risk factors‡
Relative risk 1 0.75 0.64 1.17 0.8
(95% CI) (0.31–1.79) (0.25–1.63) (0.45–3.05)
p value 0.52 0.34 0.75
*All models were adjusted for random assignment to aspirin or vitamin E. †These models were also adjusted for LDL and HDL cholesterol. ‡These models were also adjusted
for the following risk factors: LDL and HDL cholesterol, body mass index, a history of hypertension, a history of diabetes, a parental history of myocardial infarction, frequency
of exercise and current use of hormone replacement therapy.
CI  confidence interval; HDL  high-density lipoprotein; LDL  low-density lipoprotein; Lp-PLA2  lipoprotein-associated phospholipase A2; p values were calculated
by logistic regression analysis.
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subsequently developed cardiovascular events than in those
who remained free of cardiovascular events. However, this
effect was minimal and no longer statistically significant in
analyses adjusting for traditional cardiovascular risk factors.
In contrast, among the same women another marker of
inflammation, CRP, was a significant predictor in both
univariate and multivariate analyses.
Our univariate results are consistent with the finding of
Packard and colleagues (13) that Lp-PLA2 levels are some-
what higher at baseline among patients who subsequently
have cardiovascular events than in those who remain free of
cardiovascular disease. These data also confirm prior obser-
vations that Lp-PLA2 levels are highly correlated with LDL
cholesterol levels (13). However, the current data do not
find an important role for Lp-PLA2 as an independent
predictor of future cardiovascular risk in women.
There are several potential explanations for these ob-
served differences. First, our study evaluated women rather
than men, and thus it is theoretically possible that gender
differences exist for Lp-PLA2. The use of hormone replace-
ment therapy may have affected our results, although prev-
alence of hormone replacement therapy did not differ
between cases and controls, we controlled for use of hor-
mone replacement in our adjusted analysis, and no signifi-
cant difference was observed in analyses stratified by hor-
mone replacement therapy use.
Second, in contrast to the hypothesis-generating study
from Packard and colleagues that evaluated hypercholester-
Figure 1. Adjusted relative risks of cardiovascular events according to increasing quartiles of lipoprotein-associated phospholipase A2 (Lp-PLA2) and
C-reactive protein (CRP) compared to the lowest quartile. The error bars indicate the 95% CIs. The p values are for the highest quartile of plasma marker
compared to the lowest quartile. These models were adjusted for random assignment to aspirin and vitamin E and for the following risk factors: low-density
lipoprotein and high-density lipoprotein cholesterol, body mass index, a history of hypertension, a history of diabetes, a parental history of myocardial
infarction, frequency of exercise and current use of hormone replacement therapy.
Table 3. Crude and Adjusted Relative Risks of Cardiovascular Events Associated With a One-Quartile Increase in the Concentration
of Lp-PLA2 and CRP
Variable
Unadjusted*
Relative Risk
(95% CI) p Value
Adjusted†
Relative Risk
(95% CI) p Value
Lp-PLA2 1.18 (0.95–1.46) 0.14 1.05 (0.78–1.42) 0.8
CRP 1.82 (1.42–2.33) 0.0001 1.62 (1.19–2.20) 0.002
*All models were adjusted for random assignment to aspirin and vitamin E. †These models were also adjusted for the following risk factors: low-density lipoprotein and
high-density lipoprotein cholesterol, body-mass index, a history of hypertension, a history of diabetes, a parental history of myocardial infarction, frequency of exercise and current
use of hormone replacement therapy.
CI  confidence interval; CRP  C-reactive protein; Lp-PLA2  lipoprotein-associated phospholipase A2.
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olemic individuals (13), our study evaluated a much broader
cohort with lipid levels representative of the general popu-
lation. Thus, as both our study and that of Packard
demonstrate strong correlation between Lp-PLA2 and
LDL (as well as inverse correlation with HDL), it is
possible that any true predictive value of Lp-PLA2 may be
limited to those with overt hyperlipidemia. Indeed, the
strong correlation between Lp-PLA2 and LDL likely ex-
plains why the distribution of Lp-PLA2 values in our study
is lower than that observed in the Packard data despite using
an identical assay.
Third, our study involved a smaller sample size than the
West of Scotland report; nonetheless previous studies of
similar size to ours have found other novel plasma markers
of inflammation to be significant predictors of future car-
diovascular risk (10,22). Furthermore, in the present study,
baseline levels of CRP were a significant predictor of future
risk, indicating that this sample was of adequate size for
another marker of inflammation.
Finally, the randomized use of aspirin in the present
study, or pravastatin in the West of Scotland study, may
have affected the results. However, our analyses were ad-
justed for randomized use of aspirin and vitamin E, so we do
not believe this had an important effect on our results.
Conclusions. In the current data, women with the very
highest levels of Lp-PLA2 at baseline (95th percentile)
did appear to have an increased risk of future cardiovascular
events. Thus, although these data do not confirm a role for
Lp-PLA2 as a potential screening test for atherosclerotic
risk in a general population, they do support further research
regarding this unique phospholipase in sub-populations
selected for more traditional risk factors.
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